|
|
Article: Novogen's mTOR drug fights cancer stem cells.
- Article from:
- Pharma Marketletter
- Article date:
- December 8, 2008
CopyrightCOPYRIGHT 2008 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Australian drug developer Novogen says that recent data show that its novel mTOR inhibitor NV-128 has the potential to act against cancer stem cells in addition to rapidly proliferating cells in established solid tumors, according to research conducted by Yale University, USA.
Published studies indicate that mTOR pathways, in addition to their involvement in maintaining survival among rapidly-dividing cells in established tumors, also guarantee survival in cancer stem cells.
NV-128 has been shown to function as a potent ...